Search

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jenvman.2006.10.020 Byline: I. Akmehmet BalcioAlu (a), E. Tarlan (b), C. Kivilcimdan (c), M. Turker Sacan (a) Keywords: Algal treatment; Catalytic ozonation; CEH bleaching; Integrated treatment; Kraft pulp; Toxicity Abstract: Since the performance of algal treatment for pulp mill effluent decreases with increasing color intensity and AOX content, which mainly originate from the chlorine bleaching of Kraft pulp, the separated CEH bleaching effluent was pre-treated by both the conventional and the heterogeneous catalytic ozonation processes. An increase in the BOD.sub.5/COD ratio from 0.11 to 0.28 and 87% color abatement in terms of Pt-Co were achieved by catalytic ozonation, which had the best treatment performance. Biodegradability enhancement of the CEH effluent correlated well with a decrease in toxicity, high-molecular-weight-compound content, and AOX abatement. By the pre-treatment of the CEH bleaching effluent, the overall efficiencies of algal treatment of the combined pulp mill effluent in terms of the fractional removal of COD and color were increased from 76% and 53% to 86-90% and 96-99%, respectively. Effects of both the conventional and the catalytic ozonation pre-treatments on subsequent biological treatment were close to each other and they reduced the filling period of the Sequential Batch Reactor (SBR) cycle from 8 to 5 days. Author Affiliation: (a) BoAazici University, Institute of Environmental Sciences, 34342 Bebek-Istanbul, Turkey (b) Faculty of Engineering and Architecture, Department of Environmental Engineering, Selcuk University, 42075 Kampus-Konya, Turkey (c) Department of Environmental Engineering, Middle East Technical University, 06531 Ankara, Turkey Article History: Received 21 March 2006; Revised 19 October 2006; Accepted 31 October 2006

Following a one medicine approach, the development of regenerative therapies for human patients leads to innovative treatments for animals, while pre-clinical studies on animals provide knowledge to advance human medicine. Among many different biological products under investigation, stem cells are among the most prominent. Mesenchymal stromal cells (MSCs) are extensively investigated, but they present challenges such as senescence and limited differentiation ability. Embryonic stem cells (ESCs) are pluripotent cells with a virtually unlimited capacity for self-renewal and differentiation, but the use of embryos carries ethical concerns. Induced pluripotent stem cells (iPSCs) can overcome all of these limitations, as they closely resemble ESCs but are derived from adult cells by reprogramming in the laboratory using pluripotency-associated transcription factors. iPSCs hold great potential for applications in therapy, disease modeling, drug screening, and even species preservation strategies. However, iPSC technology is less developed in veterinary species compared to human. This review attempts to address the specific challenges associated with generating and applying iPSCs from companion animals. Firstly, we discuss strategies for the preparation of iPSCs in veterinary species and secondly, we address the potential for different applications of iPSCs in companion animals. Our aim is to provide an overview on the state of the art of iPSCs in companion animals, focusing on equine, canine, and feline species, as well as to identify which aspects need further optimization and, where possible, to provide guidance on future advancements. Following a “step-by-step” approach, we cover the generation of iPSCs in companion animals from the selection of somatic cells and the reprogramming strategies, to the expansion and characterization of iPSCs. Subsequently, we revise the current applications of iPSCs in companion animals, identify the main hurdles, and propose future paths to move the field forward. Transferring the knowledge gained from human iPSCs can increase our understanding in the biology of pluripotent cells in animals, but it is critical to further investigate the differences among species to develop specific approaches for animal iPSCs. This is key for significantly advancing iPSC application in veterinary medicine, which at the same time will also allow gaining pre-clinical knowledge transferable to human medicine.

The recent interest in advanced biologic therapies in veterinary medicine has opened up opportunities for new treatment modalities with considerable clinical potential. Studies with mesenchymal stromal cells (MSCs) from animal species have focused on in vitro characterization (mostly following protocols developed for human application), experimental testing in controlled studies and clinical use in veterinary patients. The ability of MSCs to interact with the inflammatory environment through immunomodulatory and paracrine mechanisms makes them a good candidate for treatment of inflammatory musculoskeletal conditions in canine species. Analysis of existing data shows promising results in the treatment of canine hip dysplasia, osteoarthritis and rupture of the cranial cruciate ligament in both sport and companion animals. Despite the absence of clear regulatory frameworks for veterinary advanced therapy medicinal products, there has been an increase in the number of commercial cell-based products that are available for clinical applications, and currently the commercial use of veterinary MSC products has outpaced basic research on characterization of the cell product. In the absence of quality standards for MSCs for use in canine patients, their safety, clinical efficacy and production standards are uncertain, leading to a risk of poor product consistency. To deliver high-quality MSC products for veterinary use in the future, there are critical issues that need to be addressed. By translating standards and strategies applied in human MSC manufacturing to products for veterinary use, in a collaborative effort between stem cell scientists and veterinary researchers and surgeons, we hope to facilitate the development of quality standards. We point out critical issues that need to be addressed, including a much higher level of attention to cell characterization, manufacturing standards and release criteria. We provide a set of recommendations that will contribute to the standardization of cell manufacturing methods and better quality assurance.

Introduction: The amount of expression of BAX and BCL-2 genes in infertile men’s sperm as well as its association with sperm parameters and DNA fragmentation index is an issue which has not been studied yet. In this research, it is assumed that up-regulation of BAX and downregulation of BCL-2 are directly associated with sperm DNA fragmentation. Methods: After obtaining semen samples from the patients by using gradient centrifugation method, the semen samples were centrifuged using gradient method in order to obtain pure sperm. Sperm is divided into three parts based on which flow cytometry, Real Time-PCR and Comet Assay techniques were conducted. After extracting RNA and producing cDNA, the amount of expression of BAX and BCL-2 genes was measured using Real Time-PCR. The amount of sperm DNA fragmentation was measured using flow cytometry and Comet Assay techniques. Based on the amount of DNA fragmentation index (DFI), samples were divided into the two groups of control (DFI

The objective of the present research was to examine the possible usage of terbinafine loaded hydrogels for vaginal application as part of vaginal candidiasis treatment. Vaginal candidiasis belongs to the most frequent gynecological disorders. Various antifungal drugs are used for its treatment, with Terbinafine being one of them. In this study, new gel formulations were prepared for Terbinafine vaginal delivery. Natural polymers such as chitosan, sodium carboxymethylcellulose, and Carbopol were used for the development of Terbinafine vaginal gels. The developed gels were examined for their viscosity and spreadability, pH and mechanical properties. The most optimal formulations were further evaluated for their in vitro release behavior and antifungal activities. In further, the cytotoxicity and irritation inducing capacity of optimum gel formulations were evaluated. In vitro drug release studies demonstrated that terbinafine release was prolonged whereas anti-candida activity in several species showed the superiority of the gels compared to the marketed product. G-5 and G-8 gels did not cause lysis, hemorrhage and coagulation, therefore, classified as non-irritant. The optimal formulations were also studied for their stability, demonstrating that they were stable for 3 months.

Since the performance of algal treatment for pulp mill effluent decreases with increasing color intensity and AOX content, which mainly originate from the chlorine bleaching of Kraft pulp, the separated CEH bleaching effluent was pre-treated by both the conventional and the heterogeneous catalytic ozonation processes. An increase in the BOD(5)/COD ratio from 0.11 to 0.28 and 87% color abatement in terms of Pt-Co were achieved by catalytic ozonation, which had the best treatment performance. Biodegradability enhancement of the CEH effluent correlated well with a decrease in toxicity, high-molecular-weight-compound content, and AOX abatement. By the pre-treatment of the CEH bleaching effluent, the overall efficiencies of algal treatment of the combined pulp mill effluent in terms of the fractional removal of COD and color were increased from 76% and 53% to 86-90% and 96-99%, respectively. Effects of both the conventional and the catalytic ozonation pre-treatments on subsequent biological treatment were close to each other and they reduced the filling period of the Sequential Batch Reactor (SBR) cycle from 8 to 5 days.